SARS-CoV-2 Seroprevalence in Healthcare Workers from the Three Teaching Hospitals in Abidjan (Cote D’ivoire) during Pandemic Waves of 2022
Published: 2023-07-15
Page: 129-138
Issue: 2023 - Volume 6 [Issue 1]
Dasse Sery Romualde *
Medical Sciences – Immunology Allergology Department, Félix Houphouet Boigny University, Boulevard de l’Université, BP V 166 – Cocody, Abidjan, Côte d’Ivoire and Immunology and Haematology Department, University Hospital of Cocody, BP V 13, Abidjan, Côte d’Ivoire.
Kouassi-Mbengue Aya Alphonsine
Medical Sciences – Immunology Allergology Department, Félix Houphouet Boigny University, Boulevard de l’Université, BP V 166 – Cocody, Abidjan, Côte d’Ivoire and Bacteriology and Virology Department, University Hospital of Cocody, BP V 13, Abidjan, Côte d’Ivoire.
Siransy Kouabla Liliane
Medical Sciences – Immunology Allergology Department, Félix Houphouet Boigny University, Boulevard de l’Université, BP V 166 – Cocody, Abidjan, Côte d’Ivoire and Therapeutic and Research Unit, National Blood Transfusion Center, Côte d’Ivoire.
Attoh-Toure Harvey
Department of Santé Publique, Institut National d’Hygiène Publique, Côte d’Ivoire.
Kouassi Yao Mathias
Centre Hospitalier Universitaire de ANGRE, Service de Medecine du Travail, Côte d’Ivoire.
Adou Adjoumanvoule Honoré
Immunology and Haematology Department, University Hospital of Cocody, BP V 13, Abidjan, Côte d’Ivoire.
Yeboah Oppong Richard
Immunology and Haematology Department, University Hospital of Cocody, BP V 13, Abidjan, Côte d’Ivoire.
Assi Aya Ursule Aniela
Immunology and Haematology Department, University Hospital of Cocody, BP V 13, Abidjan, Côte d’Ivoire.
Kouacou Amah Patricia-Victorine
Immunology and Haematology Department, University Hospital of Cocody, BP V 13, Abidjan, Côte d’Ivoire.
Seri Yida Jocelyne
Immunology and Haematology Department, University Hospital of Cocody, BP V 13, Abidjan, Côte d’Ivoire.
Moussa Salimata
Medical Sciences – Immunology Allergology Department, Félix Houphouet Boigny University, Boulevard de l’Université, BP V 166 – Cocody, Abidjan, Côte d’Ivoire.
Oura Doris
Medical Sciences – Immunology Allergology Department, Félix Houphouet Boigny University, Boulevard de l’Université, BP V 166 – Cocody, Abidjan, Côte d’Ivoire.
Kakou-Ndouba Adèle
Centre Hospitalier Universitaire de ANGRE, Service de Laboratoire de Biologie Médicale, Côte d’Ivoire.
*Author to whom correspondence should be addressed.
Abstract
Background: In view of the concern about the nosocomial character of SARS-CoV-2 known for its high variability and its strong ability to spread, this study was conducted to assess the immunogenicity status through the seroprevalence of COVID -19 among healthcare workers in the three University hospitals of Abidjan (Cocody, Angré, Treichville).
Methodology: On a sample of 275 healthcare workers randomly chosen from the different professional strata taking into account the levels of risk intensity of contamination according to services and workstations, we measured total antibodies IgG / IgM and antibodies (neutralizing) anti RBD IgG of SARS-CoV-2 using the following kits respectively: Diagnostics Evolution CHORUS Diesse® Ref 81401 SARS-CoV-2 IgM and 81400 SARS-CoV-2 IgG and Diagnostics Evolution CHORUS Diesse® Ref 81408 SARS- CoV-2 Neutralyzing Ab by a technique based on double enzyme fluorescence labeling (ELFA – Enzyme Linked Fluorescence Assay) which combines a two-step sandwich enzyme immunoassay method with fluorescence detection.
Results: The predominantly female study population was characterized by young age with rates of vaccination coverage and history of COVID-19 infection, which amount to 65,96% and 50,4% respectively. Among these health agents of which 44.1% and 46.16% worked in a context of intermediate level of risk contamination, considering respectively the department and the workstation, a very strong immunization was noted with a high seroprevalence at 93.5% of the population having produced total antibodies of IgG isotype but no IgM while 6.5% produced both IgG and IgM anti-SARS-CoV-2. Regarding anti-RBD neutralizing antibodies, 99.6% of agents are carriers.
Conclusion: This strong immunization is the response both to the vaccine, whose coverage is quite broad, and to the history of contact with the virus circulating in the population. This degree of protection obtained among healthcare workers, can be considered as collective immunity, and should be reassuring.
Keywords: Anti-RBD neutralizing antibodies, seroprevalence of COVID-19, healthcare workers, Ivory Coast
How to Cite
Downloads
References
Ministry of Health and Public Hygiene (MSHP). Coronavirus (COVID-19) Information Center. 05/23/2020.
Available: https://m.facbook.com
Doctors Without Borders (MSF). Coronavirus: Coping with the virus in Côte d'Ivoire. 03/27/2020.
Available: http://msf.fr
WHO. Weekly Monitoring Report-COVID-19. May 11-17, 2020 (Epi week 20).
Available:http://www.euro.who.int/fr/health-topics/health-emergencies/coronavirus-covid-19
Lyon Study Group on Covid19 infection (Geriatric section- Alphabetic order): Adrait A, Benoist F, Castel-Kremer E, Chuzeville M, Dupin AC, Doh S, Kim B, Favrelle L, Hilliquin D, Kanafer N, Marion E, Martin-Gaujard G, Moyenin Y, Paulet-Lafuma H, Ricanet A, Saadatian-Elahi M, Vanhems P. Fast nosocomial spread of SARS-CoV2 in a french geriatric unit lyon study group on Covid-19 infection. Infection control & hospital epidemiology as part of the Cambridge Coronavirus Collection.
DOI: 10.1017/ice.2020.99.
Wei X-S et al. A cluster of health care workers with COVID-19 pneumonia caused by SARS-CoV-2. Journal of Microbiology, Immunology and Infection.
Available:https://doi.org/10.1016/j.jmii.2020.04 .013
L. Meng F. Hua, and Z. Bian Coronavirus Disease 2019 (COVID-19):Emerging and future challenges dental and oral medicine.
Available:https://us.sagepub.com/en-us/journals-permissions
Kangqi Ng, Beng Hoong Poon, M Med Troy Hai Kiat Puar, Jessica Li Shan Quah, Wann Jia Loh, Yu Jun Wong, Thean Yen Tan, Jagadesan Raghuram. COVID-19 and the risk to health care workers: A case report Annals of Internal Medicine; 16 March 2020.
Ministry of health and public hygiene. Department of IT and Health Information (DIIS). Annual report on the health situation (RASS) ; 2017. Edition 2018
Diemer A. Modeling COVID 19, Challenges and prospects, Revue Francophone du Développement Durable, n° 15, March 2020, 72p.
Anjorin AA. The coronavirus disease 2019 (COVID-19) pandemic: A review and an update on cases in Africa. Asian Pac J Too Med [Internet]. [Cited 2020 May 7];13.
Available from: www.apjtm.org
WHO. WHO/BS.2020.2403 Establishment of the WHO international standard and reference panel for anti-SARS-CoV-2 antibody [Internet]. 2020 [Cited 2022 Apr 25].
Available:https://www.who.int/publications/m/item/WHO-BS-2020.2403
El-Hage W. et al. Health professionals facing the coronavirus disease (COVID-19) pandemic: What are the risks for their mental health? Brain. 2020;46: S73–S80.
GDPR 2021.
Available:https://www.gouv.ci/_actualite-article.php?recordID=13769
Lukas Frans Ocias, Anna Skogstam, Torbjörn Kjerstadius, Fredrik Lundin and Staffan Tevelb; Higher rate of SARS-CoV-2 IgG seropositivity in hospital-based healthcare workers compared to elderly care staff in a swedish low-prevalence region: A cross-sectional study Infectious diseases. FLIGHT. 2021;53(12):920–929.
Nathalie de Visscher, Xavier Hollemans, Aline Gillain, Anne Kornreich, Raphael Lagasse, Philippe Piette, Manfredi Ventura, Frédéric Thys. SARS-CoV-2 seroprevalence among healthcare workers after the first and second pandemic waves. Viruses. 2022;14:1535.
Fernández Crespo S, Pérez-Matute P, Íniguez ˜ Martínez M et al. Gravedad de COVID-19 atribuible a obesidad según IMC y CUN-BAE. Medicina de Familia. SEMERGEN. November–December. 2022; 48(8):101840.
Weizman O, Mika D, Cellier J. et al. Characteristics and impact of cardiovascular comorbidities on coronavirus disease 2019 in women: A multicentre cohort study. Archives of Cardiovascular Disease. 2021;114: 394-406.
An A, Liu L, Wang C, Guo H, Hao X, Wang Q, et al. Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. JAMA. 2020;323(19):1915–23.
Available:https://doi.org/10.1001/jama.2020.6130
Organization WH. Coronavirus disease 2019 (COVID-19): Situation Report. 2020;82.
Guardian T. Doctors, nurses, porters, volunteers: The UK Health Workers who have Died from COVID-19 ; 2020.
Available:https://www.theguardian.com/world/2020/apr/16/doctors-nurses- porters-volunteers-the-uk-health-workers-who-havedied-from-covid-19
Alhazzani W, Moller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving sepsis Campaign: Guidelines on the management of critically ill adults with Coronavirus Dsease 2019 (COVID-19). Intensive Care Med; 2020.
CookTM. Personal protective equipment during the COVID-19 pandemic - A narrative review. Anesthesia. 2020.
Verbeek JH, Rajamaki B, Ijaz S, Sauni R, Toomey E, Blackwood B et al. Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff. Cochrane Database System R.
Kamerow D. COVID-19: The crisis of personal protective equipment in the US. BMJ. 2020;369:m1367.
Hadyn KN Kankam, George JM Hourston, Pahalavi Ravindran, Bilal Azhar, Cassie Pope. COVID-19 antibody tests: Statistical implication. British Journal of Hospital Medicine. 2020 ;81(11).
Wölfel R, Corman VM, Guggemos W et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465–9.
Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23: 3–20.
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581: 215–220.
Juno JA, Tan HX, Lee WS, Reynaldi A, Kelly HG, Wragg K. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. 2020;26:1428–1434.
Fatma Betul Oktelik, Vuslat Yilmaz, Metin, Yusuf Gelmez, Nilgun Akdeniz, Cevriye Pamukcu, Tolga Sutlu, Murat Kose, Erdem Tuzun, and Gunnur Deniz Decline of humoral immune responses after natural SARS-CoV-2 infection can be efficiently reversed by vaccination. Canadian Journal of Microbiology. August 2022; 68(8).
Petherick A. Developing antibody tests for SARS-CoV-2. Lancet. 2020;395: 1101–1102.
Shelly Bolotin, Sarah Wilson, Michelle Murti. Achieving and sustaining herd immunity to SARS-CoV-2. CMAJ. 2021 Aug 16;193(32):E1279-E1280
DOI: 10.1503/cmaj.210892-f
Vynnycky E, White RG. An introduction to infectious disease modelling. Oxford (UK): Oxford University Press; 2010.
Hodgson D, Flasche S, Jit M, et al. Centre for mathematical modelling of infectious disease (CMMID) COVID-19 working group. The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant. Euro Surveill. 2021; 26:2100428.
3 June 2021 risk assessment for SARS-CoV-2 variant: Delta (VOC-21APR-02, B.1.617.2). London (UK) : Public Health England; 2021.
Accessible Hear : Available:https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-of-concern-variantrisk-assessments
(Accessed June 8, 2021).
Nageen Hussain, Mohsin Mumtaz, Muhammad Adil, Muhammad Waseem. ACE I/D polymorphism and In-Silico screening of potential bioactive phytochemicals against COVID-19. Bioinformatics and Biology Insights. 2022; 16:1-13.